Tenet Healthcare shares rise over 2% as Q2 earnings soar past estimates

Published 22/07/2025, 12:20
 Tenet Healthcare shares rise over 2% as Q2 earnings soar past estimates

DALLAS - On Tuesday, Tenet Healthcare Corporation (NYSE:THC) reported second quarter adjusted earnings that significantly exceeded analyst expectations.

The company’s shares were up 2.5% in pre-market trading following the announcement, as the healthcare provider raised its full-year outlook.

The company posted adjusted earnings per share of $4.02 for the second quarter, substantially beating the analyst consensus of $2.88. Revenue came in at $5.27 billion, surpassing estimates of $5.16 billion and representing a 3.2% increase YoY. Consolidated Adjusted EBITDA rose 18.6% to $1.12 billion, with an Adjusted EBITDA margin of 21.3%.

"Our strong second quarter results extend our track record of attractive same store revenue growth, operational performance driven by fundamentals, and robust free cash flow generation," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet.

The company’s Hospital segment was particularly strong, with Adjusted EBITDA jumping 25% to $623 million compared to $498 million in the same quarter last year. This improvement reflected strong same-hospital revenue growth, favorable payer mix, and disciplined expense management. The segment also benefited from $79 million in favorable Medicaid supplemental revenues related to prior periods.

In the Ambulatory Care segment, which includes United Surgical Partners International (USPI), Adjusted EBITDA increased 11.4% to $498 million. Same-facility system-wide net patient service revenues grew 7.7%, driven by an 8.3% increase in revenue per case despite a slight 0.6% decline in surgical cases.

Following these results, Tenet raised its full-year 2025 outlook, now expecting Adjusted EBITDA between $4.40 billion and $4.54 billion, a $395 million increase at the midpoint. The company also projects adjusted earnings per share of $15.55 to $16.21, well above the analyst consensus of $12.83.

The Board of Directors authorized a $1.5 billion increase to the share repurchase program, bringing the total available for repurchases to $1.78 billion as of July 22.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.